Bladder Cancer

Papers
(The TQCC of Bladder Cancer is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Single-cell RNA sequencing and spatial transcriptome analysis in bladder cancer: Current status and future perspectives11
Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer10
Predicting Recurrence and Progression in Patients with Non-Muscle-Invasive Bladder Cancer: Systematic Review on the Performance of Risk Stratification Models9
No Association Between BCG Instillations and COVID-19 Incidence in a Dutch Non-Muscle Invasive Bladder Cancer Cohort8
Urologists and Advanced Practice Providers Evaluating Hematuria7
Intravesical instillation of chemotherapy before surgery for upper tract urothelial cancer6
Clinical Trials Corner Issue 9(2)6
Management of bladder cancer in kidney transplant recipients: A narrative review5
Standard vs extended lymphadenectomy for muscle invasive bladder cancer5
Expression of PD-1 and PD-L1 in BCG-treated NMIBC5
Comparison of Robotic vs Open Cystectomy: A Systematic Review5
Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not Matter5
Evaluation of the Effects of Opium on the Expression of SOX2 and OCT4 in Wistar Rat Bladder4
Non-Muscle Invasive Bladder Cancer: Many More Patients Die With It Than Of It4
Organoid models in bladder cancer: From bench to bedside?4
Loss of Cxcr2 in Myeloid Cells Promotes Tumour Progression and T Cell Infiltration in Invasive Bladder Cancer4
A New Standard of Care for Bladder Cancer4
Efficacy of Surgery on the Primary Tumour in Patients with Metastatic Bladder Cancer: A Comprehensive Review4
Clinical Trials Corner Issue 10(2)4
Mechanism of Sex Differences in Bladder Cancer: Evident and Elusive Sex-biasing Factors3
Immune Checkpoint Inhibitors in Metastatic Bladder and Other Solid Malignancies: How Long is Enough?3
Challenging Cases in Urothelial Cancer: Case 333
Commentary on Novitas LCD3
Challenging Cases in Urothelial Cancer: Case 263
Y Chromosome Loss and Bladder Cancer3
Molecular Basis of Tumorigenesis of Bladder Cancer and Emerging Concepts in Developing Therapeutic Targets3
Systemic induction therapy in patients with locally advanced or node-positive urothelial carcinoma: Evaluating treatment outcomes3
The role of blue light cystoscopy and additional operative evaluations during first surveillance after induction therapy for high-risk NMIBC3
Adjuvant Chemotherapy Plus Radiotherapy versus Chemotherapy Alone for Locally Advanced Bladder Cancer after Radical Cystectomy2
Does Blue Light Cystoscopy Reduce Recurrences of Non-Muscle Invasive Bladder Cancer?2
Electromotive Drug Administration Chemotherapy with Mitomycin C Versus Bacillus Calmette-Guerin for the Treatment of Non-Muscle Invasive Bladder Cancer2
Clinical Trials Corner Issue 7(4)2
Challenging Cases in Urothelial Cancer: Case 272
Clinical Trials Corner Issue 8(2)2
Editorial Concerning “The Association Between Diabetes Medication Use and Tumour Characteristics at Diagnosis in Patients with Urothelial Carcinoma: A Retrospective Registry-Based Study”2
Novel Delivery Mechanisms for Existing Systemic Agents and Emerging Therapies in Bladder Cancer2
Platinum-based chemotherapy rechallenge or enfortumab vedotin after maintenance avelumab or pembrolizumab for locally advanced or metastatic urothelial carcinoma2
Patterns of Smoking Cessation Strategies and Perception of E-cigarette Harm Among Bladder Cancer Survivors2
Open vs Robotic Surgery2
0.1941499710083